Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) shot up 5.2% during trading on Monday . The company traded as high as $18.94 and last traded at $18.69. 839,585 shares traded hands during mid-day trading, a decline of 22% from the average session volume of 1,080,003 shares. The stock had previously closed at $17.77.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on CAPR. Maxim Group raised their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. Finally, Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $22.60.
Get Our Latest Stock Analysis on Capricor Therapeutics
Capricor Therapeutics Stock Performance
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The company had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Sell-side analysts anticipate that Capricor Therapeutics Inc will post -1.13 EPS for the current year.
Insider Activity
In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was acquired at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 12.00% of the company’s stock.
Institutional Trading of Capricor Therapeutics
Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics in the 1st quarter valued at about $40,000. Main Street Financial Solutions LLC raised its position in shares of Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after buying an additional 7,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Capricor Therapeutics during the 3rd quarter worth about $133,000. Rhumbline Advisers bought a new stake in shares of Capricor Therapeutics during the 2nd quarter worth about $147,000. Finally, Bank of New York Mellon Corp raised its position in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Recommended Stories
- Five stocks we like better than Capricor Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- What is an Earnings Surprise?
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- How to Invest in Biotech Stocks
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.